In a 2021 trial decision, two BMS patents were found to be valid and infringed by generic products to be made and sold by Pharmascience and Sandoz. In the subsequent costs decision, the Court declined to fix costs in a lump sum amount, and instead awarded costs at the upper end of Column V of Tariff B to be determined on an assessment.